Practice and Safety of Allergen Specific Immunotherapy for Allergic Rhinitis in the UK National Health Service: A report of 'real world' clinical practice.

Rajakulasingam, Raj K, Farah, N, Huber, P A J, Durham, S R, Clark, A T, Nasser, S M and Krishna, M T (2017) Practice and Safety of Allergen Specific Immunotherapy for Allergic Rhinitis in the UK National Health Service: A report of 'real world' clinical practice. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. ISSN 1365-2222. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs

Full text not available from this repository.

Abstract

Allergen specific immunotherapy (SIT) alleviates symptoms, improves health-related quality of life and alters the natural course of the disease in patients suffering from allergic rhinitis. It is currently delivered in the UK National Health Service (NHS) via 2 modalities namely subcutaneous injection immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The latter has a superior safety profile - anaphylaxis is a rare occurrence. Most vaccines currently employed for SIT in the UK NHS are unlicensed and available on a named-patient basis and prescribed in secondary care by a specialist. This article is protected by copyright. All rights reserved.

Item Type:	Article
Additional Information:	This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Subjects:	QW Microbiology. Immunology WD Diseases and disorders of systemic, metabolic or environmental origin > WD300 Hypersensitivity. Allergy
Divisions:	Clinical Support > Pathology
Depositing User:	Miss Emily Johnson
Date Deposited:	26 Jan 2018 13:51
Last Modified:	26 Jan 2018 13:51
URI:	http://www.repository.uhblibrary.co.uk/id/eprint/1461

Actions (login required)

View Item